{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-26-000030","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-10-13T12:25:13+00:00","discovered_at":"2026-10-13T12:30:00.151879+00:00","generated_at":"2026-10-13T12:30:03.328428+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"iBio's IBIO-610 plus semaglutide cut lean-mass share of NHP weight loss to 6% vs 22%","bullets":["In an 8-week obese NHP study (n=6 per group), fat was 93% of weight lost with single-dose IBIO-610 plus twice-weekly semaglutide, vs 77% with semaglutide alone.","Lean mass made up 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone.","IBIO-610 produced 97% reduction in active Activin E serum levels at week 8 after a single IV dose; NHP half-life was 33.2 days, potentially supporting twice-yearly human dosing.","Data presented in an oral session at the EASD Annual Meeting on Oct. 1, 2026; iBio plans to start first-in-human trials of IBIO-610 in the first half of 2027.","CEO/CSO Martin Brenner framed IBIO-610 as addressing the quality-of-weight-loss gap left by GLP-1 therapies; all results are preclinical."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-26-000030","json":"https://secwatch.observer/filing/0001420720-26-000030.json","markdown":"https://secwatch.observer/filing/0001420720-26-000030.md","text":"https://secwatch.observer/filing/0001420720-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/0001420720-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/ibio-20261013x8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T12:30:03.328428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}